Lupine Publishers | Orthopedics and Sports Medicine Open Access Journal (OSMOAJ)
For more Orthopedics and Sports Medicine Open Access Journal (OSMOAJ)
Please Click Here: http://www.cosmosimpactfactor.com/page/journals_details/5256.html
Lupine Publishers | Orthopedics and Sports Medicine Open Access Journal (OSMOAJ)
For more Orthopedics and Sports Medicine Open Access Journal (OSMOAJ)
Please Click Here: http://www.cosmosimpactfactor.com/page/journals_details/5256.html
Lupine Publishers | Open Access Journal of Oncology and Medicine (OAJOM)
Introduction
Multiple myeloma (MM) accounts for approximately 2% of all malignancies and 13% of hematological malignancies worldwide [1]. MM is the second most common hematologic malignancy [1] and it is a neoplasm of clonal plasma cells which originate from the B-cell lineage and develop after lineage commitment in the bone marrow of progenitor cells [9]. Cutaneous involvement in patients with multiple myeloma is rare and it usually represents of a poor prognosis. Cutaneous involvement indicates an increased tumor burden. The most common cause of cutaneous involvement is due to direct extension from underlying bone lesions of MM or solitary plasmacytoma of bone [2]. It is very rare to have primary cutaneous plasmacytoma [3].
Case Presentation
We present the case of a friendly Caucasian American 70-yearold female with no significant PMH who initially presented to Ruby Memorial Emergency Department in November 2015 with persistent back and left side pain. At that time, she began to notice weakness and some numbness in lower extremities and along with the increasing low back pain decided to seek medical attention and presented to the hospital. On admission, CT thoracic spine (11/16/15) revealed a T5 wedge compression deformity. CT lumbar spine revealed degenerative changes with diffuse osteoporosis. MRI thoracic spine (11/17/15) revealed a T5 burst fracture with retropulsion, focal kyphotic deformity, severe central canal stenosis, possible pathologic fracture deformity, And possible cord contusion at T5. CBC on admission revealed WBC 5.1 with normal differential, Hgb 11.5 with MCV 105.3 and platelet count 170,000. BMP normal, creatinine 0.75, corrected calcium 10.2. Subsequently, she underwent a posterior spinal fusion T3-T8, left costotransversectomy with left pedulectomy and subtotal corpectomy (excision of tumor) via transpedicular approach with placement of anterior cage, T5 laminectomy, and T6-7 partial laminectomy. Pathology revealed a tumor composed of sheets of atypical plasmacytoid cells positive with immunostain for CD138 and negative for pancytokeratin, CD20, and CD3. Insufficient tissue remained for kappa and lambda ISH. The finding was consistent with plasma cell neoplasm. SPEP revealed an M spike seen in the gamma, consistent with monoclonal gammopathy. Random UPEP/ IFE revealed a monoclonal lambda protein without detectable associated IgG, IgA or IgM heavy chain. In December, SPEP/IFE revealed an IgG Lambda monoclonal protein (5.95 g/dL). Free light chain ratio 0.013 (Kappa 0.80 mg/dL, Lambda 60.50 mg/dL). Quantitative IgG 5950 g/dL. Hgb 9.4 with MCV 98.5. Creatinine 0.62. Corrected serum calcium 11.2. Albumin 2.0. Beta 2 microglobulin 4.25. Skeletal survey reveals diffuse osteolytic process with multiple calvarial, vertebral body and rib lesions identified. T3-T8 posterior spinal fusion for pathological T5 compression fracture noted.
She had a bone marrow biopsy/aspirate which revealed 47% lambda restricted plasma cells, with marked atypia including a plasmablastic morphology. Preliminary FISH results indicate multiple trisomies, 1q21 gain, del (13q14) and a non-standard IGH rearrangement-t(8;14). Hyperdiploidy detected. She was diagnosed with IgG Lambda Multiple Myeloma. ISS Stage II, DS IIIA. Soon thereafter, she was started on a bortezomib-based triplet regimen - bortezomib, cyclophosphamide, dexamethasone (CyBorD). She completed 4 cycles. In April 2016, SPEP/IFE revealed an IgG Lambda monoclonal protein - not quantified. Quantitative immunoglobulins: IgG 1013 mg/dL. Free light chain assay revealed a ratio of 1.169 (kappa 2.98 mg/dL, Lambda 2.55 mg/ dL). CBC normal. Hgb 13.2. Serum creatinine 0.59. Serum calcium 9.7 (corrected). Serum albumin 3.0 g/dL. Beta 2 microglobulin 2.65 mcg/mL. Skeletal survey demonstrated new evidence of L5 pathological compression fracture. A repeat bone marrow biopsy revealed a variably cellular marrow (10-50%). Maturing trilineage hematopoiesis noted. No atypical plasma cell infiltrate (<5% by CD138 ICH). Cytogenetics normal. Unable to run FISH. At the end of the month, her regimen switched to Lenalidimide/Dexamethasone and she completed 4 cycles. In August, she began maintenance therapy with Lenalidomide at 10 mg daily. She then presented with multiple skin papule skin lesions (Figure 1) mostly on her gluteal region. In January 2017, she had a left gluteal skin biopsy consistent with plasma cell neoplasm with high grade features (plasmablastic differentation) In February 2017, SPEP/IFE revealed a IgG Kappa monoclonal protein (not quantified). IgG level 2303 mg/dL. Free light chain assay reveals a ratio of 1.31 (Kappa 12.63 mg/dL, Lambda 9.62 mg/dL). She completed radiation therapy to left gluteal skin - received 30 Gy/15 fractions. SPEP/IFE revealed a IgG Kappa monoclonal protein (not quantified). IgG level 2357 mg/dL. Free light chain assay reveals a ratio of 1.47 (Kappa 12.20 mg/dL, Lambda 8.32 mg/dL). In March 2017, she was started on Pomalidomide/ Dex. Unfortuatnely she was found to have progression of her disease noted. She was then started on Daratumumab which she could not tolerate and was then started on Carfilzomib/Dex. She has received multiple radiation therapy to her left gluteal region, mid back and left upper lip with significant resolution in all areas. In February 2017, she was admitted to Ruby with worsening pain and lesions located in her lower extremities and edema (Figure 1). Peripheral duplex was obtained and blood cultures to rules out a venous clot and infection respectively. A biopsy was obtained (Figure 2) which showed cutaneous involvement of her multiple myeloma. Radiation Oncology was consulted, and she was started on palliative radiation for 5days which initially improved her pain and swelling. Unfortunately, her lesions continue to arise with intermittent, short lived responses to systemic therapy. Her lesions now too widespread for continued radiation therapy. She noticed lesion in her scalp. She continues to follow up in clinic where she was started on single agent Doxil 40 mg/m2 every 4 weeks. Sadly, she continues have progressive cutaneous disease around the flank, abdomen, and bilateral thighs.
Discussion
We present an interesting case of cutaneous involvement of multiple myeloma where although the patient has been on multiple therapies continues to progress in her disease. Her case is interesting from other presentations in that they don’t usually do not describe the course of regimen used in treatment. The standard of care of cutaneous involvement revolves controlling the origin of the disease. One specific treatment that we tried was localized radiation. There is not much data or past literature discussing the use of radiation or its efficacy. Unfortunately for our case, the treatment only helped briefly. Most common involvement for MM is soft tissue involvement of the upper airway and oral cavity. They usually consist of firm, erythematous, nontender nodules involving the neck, ears, shoulders, axillae, chest, abdomen, and dorsum of the hands [11]. The first reported case of skin involvement in a person with MM was presented by Bruno Block in 1910. He described a patient who had small reddish macules that evolved into brown reddish papules and nodules with scale crusts. Histologically these lesions showed epidermal necrosis. He eventually had disease in pleura, stomach, and heart and passed away two years later [3]. A review of literature reveals that there are over 100 described cases. The age ranges from 36 to 81 with a median of 60 years old. Numeric date was available for 87 cases and 63 of them were male and 24 were female [4]. Cutaneous involvement of MM may appear in area of the skin, but it has been reported most commonly on the trunk and abdomen. Skin lesions is commonly described as papules or nodules that measure 1-5 cm in diameter with firm consistency, smooth surface, and a red or violaceous color [5]. Some authors reported that cutaneous involvement of MM only occurs when the tumor mas burden is over 2-3 kg [6]. Cutaneous involvement in patient with MM and extramedullary plasmacytoma generally appears late during the disease. On average, death occurred within 12 months after the diagnosis. Autopsy of these patients reveal extensive plasmacytic infiltration of multiple organs [7].
A review of the cases of MM involving the skin revealed that 40 cases were IgG, 21 cases were IgA, and 9 cases were IgD. The risk of cutaneous involvement by MM is not associated with a particular class of myeloma immunoglobins. Histopathologically, the lesions of MM involving the skin show 2 patterns: nodular and diffuse interstitial [6]. (Figure 2, 3). The worldwide incidence of myeloma is 86,000 cases annually. Mortality rate in MM is high with a median survival of 50-55 months and 63,000 deaths being reported worldwide each year [8]. Significant advances have been made in understanding multiple myeloma (MM) and its precursor diseases. These advances include the gain in knowledge in the underlying pathophysiology, Food and Drug Administration (FDA) approvals of novel therapies with meaningful efficacy and the science in underlying disparities in patients with MM [9].
Read More about Lupine Publishers
Lupine Publishers | Orthopedics and Sports Medicine Open Access Journal (OSMOAJ)
Goal: Systematic review of current therapeutic options for Idiopathic Adhesive Capsulitis of the shoulder (IAC).
Materials and Methods: Research carried out in the MEDLINE / Pubmed database using MeshTerms: “adhesive capsulitis”, “frozen shoulder”, “treatment”. The articles in Portuguese or English published were selected, after which non-relevant articles were excluded based on the title, reading of the abstract and full article.
Results: Physical therapy has proven to be beneficial, either isolated or concomitantly with other therapeutic approaches. Options like capsular distention, manipulation under anesthesia and arthroscopic surgery have reported good results, especially in refractory cases. No significant benefits were found with the use of oral corticosteroids, NSAIDs or acupuncture. New treatment options are currently being tested with promising results.
Conclusions: There are several effective options for the treatment of Adhesive Capsulitis. In the early stages, conservative measures should be chosen, with special emphasis on physical therapy within the limits of pain associated with low-dose intraarticular injection of corticosteroids. In refractory cases, more invasive treatment options should be suggested namely capsular distension and manipulation under anesthesia.
Keywords: Adhesive Capsulitis; Frozen Shoulder; Diagnosis; Treatment
Adhesive capsulitis is a pathology characterized by a spontaneous onset of insidious and diffuse pain in the shoulder associated with progressive restriction of active and passive motion of the glenohumeral joint [1]. Almost 150 years after its first description, it remains an uncertain entity. The proper terminology, used for the first time in 1945, is also controversial, since this condition is related to the contraction and thickening of the glenohumeral capsule, in particular the coracohumeral ligament in the rotator’s interval [1, 2]. The disease is classified as primary and secondary. The primary entity has an unknown etiology and will be addressed in this review [3]. Secondary adhesive capsulitis is caused by an event or triggering condition such as trauma, surgery or a systemic condition such as diabetes mellitus, thyroid abnormalities, etc. [2]. Diabetes mellitus has the most established connection, with an estimated incidence of adhesive capsulitis in 20% of this population [4]. The prevalence of this pathology in the general population is believed to be 2-5%. However, it is believed that the true prevalence is actually inferior and difficult to determine, not only because vague and insidious symptoms lead to numerous diagnostic errors, but also because most studies include specific comorbidities with a greater incidence of IAC than within the general population [2, 3, 5, 6].
This pathology occurs mainly between the 4th and 6th decade of life and is thought to be more frequent in women [7]. Some argue that it affects the non-dominant side more often and that in about 20-30% of cases it recurs on the contralateral shoulder, usually in the first 5 years after the resolution of the primary condition [1, 3, 7-10]. Although considered a benign condition, with a self-limiting pattern and resolution within 2 to 3 years, it is estimated that 20-50% of the cases continue with mild to moderate pain and restricted movement over a period of up to 10 years [4, 11]. The etiology of adhesive capsulitis also remains uncertain and theories vary. However, the evidence points to a chronic inflammatory response with subsequent capsular fibrosis that possibly involves increased deposition of cytokines such as TGF-β, PDGF, TNF-α and IL-1 [1-3, 7]. There are also studies that advocate an association with Dupuytren’s contracture that may involve the same abnormalities. The changes found include: contraction and fibrosis of the coracohumeral ligament, thickening and fibrosis of the rotator’s interval, contraction of the anterior and inferior capsule, decrease in joint volume, obliteration of the axillary recess and neovascularization [2, 3]. The evolution of this pathology can be divided into three phases. The acute initial phase (freezing phase) is characterized by the insidious appearance of diffuse pain and restriction of the range of motion of the glenohumeral joint, which lasts for about 10 to 36 weeks (Figure1). In the second phase (frozen phase), for about 4 to 12 months, the pain slightly decreases but the movement restriction continues, with almost total loss of external rotation. In the resolution phase (thawing phase) there is spontaneous progressive improvement in the range of motion and resolution of pain. This last phase has an average duration of 30 months (12 to 42 months) [3, 6-8]. Numerous studies have attempted to determine which treatment is the most effective for adhesive capsulitis. However, currently, despite the various options, there is still no consensus among the authors regarding the most advantageous treatment and at what stages of the disease it should be performed [4, 12, 13]. Most of the evidence is inconclusive due to the precarious methodology of the studies [14].
There is no standard diagnostic method for this condition, which is based on clinical examination, exclusion of differential diagnosis, normal radiographic appearance and findings on ultrasound, magnetic resonance imaging (MRI) and arthrographic magnetic resonance imaging (arthroMRI) [2, 15]. The early diagnosis of adhesive capsulitis is extremely important since it allows the institution of therapy before the progression of thickening and contracture of the capsule observed in advanced stages [15]. Clinically, an insidious diffuse pain with at least four weeks that interferes with the activities of daily life should be investigated. Night pain is also common, with the patient complaining of more severe pain while sleeping on the affected side. Painful restriction of active and passive motion of the glenohumeral joint is also frequent, with special emphasis on external rotation (more than 50% of restriction) and elevation (less than 100ᴼ) [1, 3]. Radiographs do not normally show any changes, except for a slight periarticular osteopenia of the humeral head and neck, which can occasionally be found [1, 3, 7,15]. The most important role of radiography is the possibility of ruling out other pathologies such as calcifying tendinitis of the rotator cuff, osteoarthritis, avascular necrosis or fractures that can also cause painful movement restriction and be misdiagnosed as adhesive capsulitis [15, 16]. For a more accurate diagnosis, ultrasound, MRI or ArtroRM are usually necessary [15]. With the use of ultrasound, the diagnosis can be suspected by a thickening of the structures in the rotator’s interval, namely of the coracoumeral ligament, and restriction of the motion of the supraspinatus tendon during abduction. With echodoppler, synovial inflammation can be readily detected (Figure 2), which has advantages when compared with MRI and ArtroMRI since it is less expensive, faster, more dynamic and easily accessible [2, 3, 15].
MRI is an effective non-invasive diagnostic tool, not only for cases where this condition is suspected, but also provides information that can help the surgeon differentiate between the different stages of the disease [3,15,17]. Although it is not diagnostic, some argue that the degree of capsular thickening, measured in the axillary recess, can be correlated with the clinical stage of adhesive capsulitis [16]. Among other findings, several characteristics of this condition can be seen: thickening of the coracohumeral and capsular ligament in the rotator’s interval and axillary recess (greater than 4 mm) and obliteration of the subcoracoid space by the thickened capsule (Figure 3). Thus, MRI allows for early diagnosis, determining the pathophysiological stage and ruling out differential diagnosis [15]. ArtroMRI allows for visualization of basic disease characteristics, namely the thickening of the coracohumeral ligament and the capsule, possibly with greater precision than the MRI, but also to detect decreased joint volume [1,3,15]. However, some claim that both MRI and ArtroMRI, despite the useful findings, are not indicated as a means of diagnosis for adhesive capsulitis and should only be used as a method of excluding other intra-articular pathologies [3].
A great variety of therapeutic options are available for the treatment of adhesive capsulitis. During the early stages, where pain predominates, treatment should be directed towards pain relief and patients should be advised to limit activities according to their tolerance [7]. The secondary objective is to improve the range of motion [4] and restore the ability to perform the daily activities.
Conservative treatment, such as physical therapy, is recommended in the freezing phase [4, 6]. Most patients will recover with this initial management [16, 18, 63]. The conservative approach has a wide range of modalities, with well documented results.
Isolated physiotherapy is a widely accepted treatment option, which can also be used as a complement to other therapeutic modalities [1, 3], with some reports considering it to be crucial for success [4]. Currently, various techniques are used, such as the application of moist heat, strengthening exercises, stretching and manual exercises [7, 19, 20]. Several studies have compared these modalities with different conclusions, making it difficult to determine which is the most beneficial [4, 9,20]. Most studies in which comparisons were made between two interventions did not detect significant differences between the techniques [21]. In several investigations, the techniques of high and low grade glenohumeral mobilization were compared, with significant improvement after 12 months for both approaches. Some authors concluded that the intensive approach was significantly more effective in restoring mobility and reducing disability [20-22]. In contrast, others argue that the amount of force applied should be adjusted to the patient’s condition, limited to their tolerance, because if excessive force is applied, it can produce extreme pain, periarticular injury or abandonment of treatment, thus, one should opt for prolonged progressive low-load stretches, a method considered safe and effective [7, 9, 23].
In a study with level I evidence, the effectiveness of three different physical therapy modalities was compared: group physiotherapy, individual physiotherapy and home exercise program. Not only was there a greater degree of symptomatic improvement in the shoulder, but also better anxiety control with group physiotherapy. There were also benefits in relation to costeffect and self-management in this group. However, standard physical therapy remains a good alternative and has been shown to be significantly better than unsupervised home exercises [6]. In another study with level II evidence in which regular physical therapy was compared with a new contraction technique, the new approach demonstrated greater recovery of the function of the glenohumeral joint when compared to the group of normal physical therapy. However, further studies are needed to validate this conclusion [24]. Some authors advise a Multimodal Care program that includes mobilization, shoulder orthoses and stretches with strengthening exercises, which appears to be beneficial for symptomatic relief, although the evidence seems limited [25, 26].
Horst, et al. compared structural-oriented (conventional) physical therapy with an activity-oriented physiotherapeutic treatment, concluding that therapy based on performing activities appears to be more effective for pain reduction and the ability to perform daily life activities than conventional treatment methods [64]. When compared to ad initium arthroscopy, physical therapy produces similar results, but without surgical aggression and with a better cost-benefit ratio [27]. Lamplot, et al. in a level III cohort study [57] found a decrease in the need of a second intra-articular injection in the patients who underwent physical therapy following the first injection, underlining the major role of physiotherapy in the treatment of IAC.
Corticosteroids have been administered to the glenohumeral joint in several ways, namely anterior, lateral and / or posterior approach [4, 28]. Although clinically it is common practice to use an injection via an anterior or posterior approach, studies comparing different techniques have not found significant differences in the improvement of pain or range of motion [11, 29]. Cho, et al. [60] in a randomized trial study found that the efficacy of corticosteroid injection into the subacromial space in IAC was inferior to intraarticular injection up to 12 weeks. However, a combination of injection sites had an additive effect on the benefits in the internal rotation angle There is no agreement regarding the optimal dose of intra-articular corticosteroids. Yoon et al. did not detect a significant difference between the low (20 mg) or high (40 mg) dose groups, indicating, due to its side effects, the preferential use of low dose corticosteroids for the treatment of adhesive capsulitis [30].
A limitation of the use of intra-articular corticosteroids is the fact that blind injections can be inaccurate in about 60% of cases. The current use of ultrasound or fluoroscopy-guided injection can overcome this problem [8, 16]. It has been shown in several studies that this practice improves accuracy and results compared to the “blind-technique” [3, 31]. There is evidence that the initial corticosteroid injection can reduce pain and improve range of motion in the short term and that its benefit can be increased in the short and medium term when these injections are followed by physical therapy [11, 21, 57]. Kraal et al. in a two center, randomized controlled trial, found that additional physiotherapy after corticosteroid injection improves ROM and functional limitations in early-stage IAC up to the first three months, underlining the good results of these techniques combined [61].
When compared as isolated treatments, there is strong evidence in benefit of corticosteroid injection in the short term (4-6 weeks), compared to isolated physical therapy, but not in the long term [11, 22, 30, 32, 33]. In a study that compared the injection of corticosteroids and the benefit of isolated intra-articular analgesics, significant improvements were found with the administration of corticosteroids [22]. Hettrich et al. showed that corticosteroid injections decreased fibromatosis and myofibroblasts in the shoulders with IAC [58]. On the other hand, some studies conclude that this form of treatment has results similar to isolated physical therapy or more invasive treatments such as MUA and arthroscopy [29, 32, 34], confirming the high degree of controversy surrounding this disease.
Ultrasound-guided interventions have several strong points like the lack of radiation and the possibility of real time visualization of the needle’s trajectory. This technique has advantages when compared to fluoroscopy, CT and MRI since these are less practical, more time consuming and involve radiation or a specific needle [35]. One of the modalities of capsular distention is based on the use of hyaluronic acid. The ideal time between injections is one week and the effects are usually seen after the second injection [36]. In a study comparing this approach with the injection of corticosteroids, it was found to be more effective in favor of distension with hyaluronic acid in passive external rotation (10ᴼ) at 2 and 6 weeks, with no significant differences in pain relief or in function recovery. This study also concluded that this approach is a good alternative to intra-articular injection of corticosteroids and can be especially useful in patients with diabetes mellitus or contraindicated to the use of corticosteroids [37]. Calis et. al. also concluded that this approach is effective in the treatment of adhesive capsulitis when compared to isolated corticosteroid injection, physical therapy and exercise [36]. Ultrasound-guided capsular hydrodistension is a procedure that aims to distend the capsule contracted by increasing pressure by injecting large amounts of sodium chloride into the glenohumeral joint [9]. There is evidence that it provides relief from pain and improves range of motion, especially when it is followed by physical therapy [29, 38]. Other studies have found that saline distension with or without concomitant corticosteroids are more effective than MUA, describing better results after 6 months with this procedure, with less risk, and resulting in a higher level of satisfaction on the part of patients. However, the effects do not seem to persist beyond 6-12 weeks [9, 29, 39, 40].
This technique can be performed with sodium chloride, local anesthetic, steroids, contrast or air. It should be reserved for patients who do not improve despite physical therapy [22]. It is also considered a good therapeutic option for rapid symptom relief. Better results were observed when followed by physical therapy [38]. There was no significant difference in the efficacy of capsular distention with or without corticosteroids in most investigations [39, 41]. However, Rysns et al. when comparing distension with corticosteroid injection with placebo saline injection to determine whether the results were due only to the increase in volume, found a significant improvement with the concomitant use of corticosteroids [32].
The use of Extracorporeal Shock Wave Therapy (ESWT) in the treatment of several shoulder diseases, namely in calcific tendinopathy of the rotators cuff, is well documented. Several studies evaluate its usefulness in IAC, with positive effects such as a quicker return to daily activities and quality-of-life improvement [66, 67], at least in the short-term. El Naggar, et al. compared the effectiveness of radial extracorporeal shock-wave therapy versus ultrasound-guided low-dose intra-articular steroid injection in in diabetic patients, concluding that in the short-term follow-up ESWT was superior to a low-dose intra-articular steroid injection in improving function and pain in diabetic patients with shoulder IAC [68], therefore validating it as an alternative to steroid injections in diabetic patients with this pathology. This particular usefulness of ESWT in diabetic patients has also been documented in other studies [69, 70]. Many prospective randomized trials are underway to further validate ESWT as a treatment option in IAC, especially in the diabetic population.
Oral non-steroidal anti-inflammatory drugs, although widely used in the initial / inflammatory phases for pain relief in the short term, did not prove their benefit when compared with placebo [3, 7, 9]. Prednisone at a dose of 40 to 60 mg / day for two to three weeks provides faster relief of symptoms in the short term, but their effects are not significant after 6 weeks and there is no evidence that they shorten the duration of disease [28]. Some studies have concluded that there may be a moderate short-term benefit with acupuncture associated with exercise [22], however the usefulness of this therapeutic approach remains undetermined [21]. Calcitonin is a polypeptide hormone secreted from parafollicular cells of the thyroid that has been used for pain control in several pathologies. Although its pathophysiology is not totally clear, it is thought to diminish the inflammatory response and increase endorphins’ release [71, 72]. Rouhani, et al. in a double-blinded randomized controlled trial compared intranasal calcitonin versus placebo for 6 weeks and found great improvement of shoulder pain, ROM, and functional scores in the calcitonin group [71]. Currently the dose recommendation is 200 U (1 puff) daily [73]. Regarding future approaches, Badalamente, et al. [53, 54] published two papers evaluating the applicability of extra-articular collagenase injections in the anterior shoulder capsule. In a placebo controlled doubleblind RCT, they found improvements in shoulder motion, functional score and pain control in the collagenase group in their 1.8 years follow up. In a randomized pilot study comparing subcutaneous adalimumab with local corticosteroids, Schydlowsky et al. found no benefits with the anti-TNF agent in the treatment of frozen shoulder [55] These new treatment approaches for IAC must undergo further investigation, but, if developed, could also play a role in the management of other arthrofibrosis [56].
Surgical treatment of adhesive capsulitis is considered after failure of conservative treatment. It is estimated that 10% of patients do not respond to non-invasive treatment [25, 26]. There are no defined guidelines for this transition. However, regardless of the chosen conservative treatment, a surgical approach is only considered after about 6 months of non-surgical treatment without clinical improvement [3, 4, 8, 12, 16, 42]. Its benefit in refractory / severe adhesive capsulitis is proven and well documented [43], and some studies have found that in patients with high risk factors such as diabetes mellitus, and those who suffer chronic symptoms or bilaterally affected, early surgery is beneficial [65]. In a recent questionnaire to health professionals, only 3% recommended surgical treatment in the acute phase, while 47% recommended it in the second and third stages of the disease [4]. Surgical treatments should be complemented with an appropriate physical therapy scheme [63]. Some advocate the initiation of immediate postoperative physiotherapy, with light isometric exercises after 1-2 weeks and isotonic exercises in the following 2-3 weeks. Ideally the range of motion without complete restriction should be achieved in 12 to 16 weeks [4].
This procedure involves stabilizing the shoulder blade with flexion, abduction and adduction, followed by maximum internal and external rotation. Some studies advocate good results with this technique, mainly in terms of range of motion [44], others have not found significant differences in comparison with other treatments [45]. There is modest evidence of the benefit of MSA in relieving pain and recovering mobility when followed by physical therapy [46]. However, some authors have not found significant differences in the improvement of pain, function, disability or range of motion in the short, medium or long term between isolated MUA and exercise-associated MUA when compared to physical therapy alone [21, 45]. When compared with arthroscopy, better results were observed with arthroscopic distention at 6 months [21]. However, more recently, Schoch et al. in a study with the largest series of patients undergoing surgical treatment of adhesive capsulitis with a direct comparison between MUA, MUA/Capsular release (CR), and CR alone, found significant improvement of the ROM in all surgical modalities, however, the MUA group had the greatest external rotation, postoperatively [59]. MUA has been associated with several intra-articular iatrogenic complications such as humeral fracture, glenohumeral dislocation, brachial plexus injury rotator cuff injury and hemarthrosis [4, 46, 47]. Nonetheless, some argue that these lesions have no clinical relevance or that they can be minimized by performing the technique properly [44, 47]. Others advise that this procedure should be avoided in patients with osteoporosis, osteopenia or previous MUA recurrence [46]. Another limitation of manipulation is the fact that stretching the tissues can cause severe pain after the end of the anesthesia effect, leading to delays in recovery [8].
Arthroscopy allows the distension of the glenohumeral joint to be combined with a series of other procedures, such as adhesions release, opening of the rotator’s interval, circular capsulotomy and section of the coracohumeral ligament. This procedure must be followed by physiotherapy [2]. Several studies have supported the role of this approach as safe and effective in the treatment of adhesive capsulitis [27, 48, 49]. Several authors support the use of arthroscopy, claiming that, in addition to the good results obtained, it makes it possible to deepen and confirm the diagnosis by a complete assessment of the shoulder joint during the procedure [4, 8]. Some, on the contrary, argue that currently the evidence does not support the use of this technique [50], underlining the prevalent controversy in the treatment of this pathology. Recent investigations have not shown greater benefits in range of motion with more extensive release of the capsule (anterior release vs. Anterior plus posterior release) [9, 62]. Sivasubramanian et al. made a systematic review and meta-analysis which suggests that less extensive releases may result in better functional and pain scores. The addition of a posterior release appears to increase early internal rotation, but doesn’t maintain that benefit over time. No benefit was found with the complete 360 release [62]. Some authors suggest that arthroscopic distension can be associated with concomitant manipulation, with improved outcomes [8]. In a study comparing arthroscopy plus manipulation against isolated intraarticular corticosteroid injection, both approaches were effective in improving pain and range of motion. However, the objectives were achieved sooner by the group that underwent arthroscopy (6 weeks vs 12 weeks) [51]. Grant, et al. compared arthroscopic distention with MUA finding a small benefit in favor of arthroscopy alone or in association with manipulation, advising this technique due to the lower number of complications [52]. On the other hand, Jerosch et al. concluded that this therapy has a greater benefit in reducing pain and improving movement, even in the long term, being a valuable, more precise, controlled option with fewer complications than manipulation [12].
Surgical treatments have changed from open to arthroscopic procedures and, therefore, the open technique, although effective, has fallen into disuse [4]. It is rarely used nowadays, but may be beneficial in cases refractory to MUA and arthroscopy [9].
Lupine Publishers | Orthopedics and Sports Medicine Open Access Journal (OSMOAJ)
Lupine Publishers | Orthopedics and Sports Medicine Open Access Journal (OSMOAJ) Abstract Background: Recurrent dislocation of the shou...